Maxcyte, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

25 Mar 2026

MXCT

10-K: MaxCyte 2025 Annual Report: Losses Widen Amid Restructuring

MaxCyte reported a wider net loss of $44.6 million in 2025, driven by decreased core revenue and a workforce reduction, despite strategic acquisition and platform expansion.

NASDAQ

11 Mar 2025

MXCT

Maxcyte, INC

10-K: MaxCyte Reports FY2024 Results, Highlights Strategic Growth Initiatives

MaxCyte's 10-K filing summarizes the company's financial performance for 2024, highlighting its cell engineering technology and strategic platform license agreements.

NASDAQ

12 Mar 2024

MXCT

Maxcyte, INC

10-K: MaxCyte Reports Full Year 2023 Results, Highlights Strategic Partnerships and Growth Initiatives

MaxCyte's 2023 annual report details financial performance, strategic partnerships, and future growth plans in the cell engineering and life sciences sector.